XML 32 R20.htm IDEA: XBRL DOCUMENT
v3.21.2

Other Income (Expense), Net | 9 Months Ended
--- | ---
Oct. 01, 2021
Other Income and Expenses [Abstract] |
Other Income (Expense), Net | OTHER INCOME (EXPENSE), NET The following sets forth the components of the Company’s other income (expense), net:
| Three-Month Period Ended |  | Nine-Month Period Ended |  |
| October 1, 2021 |  | October 2, 2020 |  | October 1, 2021 |  | October 2, 2020 |  |  |  |
Other components of net periodic benefit costs | $ | 9 |  |  | $ | 4 |  |  | $ | 31 |  |  | $ | 14 |  |  |  |  |
Investment gains (losses): |  |  |  |  |  |  |  |  |  |  |
Realized investment gains (losses) | 10 |  |  | — |  |  | 48 |  |  | — |  |  |  |  |
Unrealized investment gains (losses) | 118 |  |  | 3 |  |  | 282 |  |  | (10) |  |  |  |  |
Total investment gains (losses) | 128 |  |  | 3 |  |  | 330 |  |  | (10) |  |  |  |  |
Gain on sale of product lines | — |  |  | — |  |  | 13 |  |  | 455 |  |  |  |  |
Total other income (expense), net | $ | 137 |  |  | $ | 7 |  |  | $ | 374 |  |  | $ | 459 |  |  |  |  |
Other Components of Net Periodic Benefit Costs The Company disaggregates the service cost component of net periodic benefit costs of the noncontributory defined benefit pension plans and other postretirement employee benefit plans and presents the other components of net periodic benefit cost in other income (expense), net. These other components of net periodic benefit costs include the assumed rate of return on plan assets, partially offset by amortization of actuarial losses and interest. Investment Gains (Losses) The Company estimates the fair value of its investments in equity securities using the Fair Value Alternative and records adjustments to fair value within net earnings. Additionally, the Company is a limited partner in partnerships that invest primarily in early-stage companies. While the partnerships record these investments at fair value, the Company’s investments in the partnerships are accounted for under the equity method of accounting. The investment gains (losses) include realized and unrealized gains and losses related to changes in the fair value of the Company’s investments in equity securities and the Company’s equity in earnings of the partnerships that reflect the changes in fair value of the investments of the partnerships. Gain on Sale of Product Lines During the first quarter of 2021, the Company divested certain product lines for a cash purchase price, net of cash transferred and transaction costs, of $26 million and recognized a pretax gain on sale of $13 million ($10 million after-tax). The divested product lines generated revenues of approximately $88 million in the Environmental & Applied Solutions segment in 2020. The divestiture of these product lines did not represent a strategic shift with a major effect on the Company’s operations and financial results and therefore is not reported as a discontinued operation. As a condition to obtaining certain regulatory approvals for the closing of the Cytiva Acquisition, the Company was required to divest certain of its existing product lines in the Life Sciences segment that in the aggregate generated revenues of approximately $170 million in 2019. On April 30, 2020, the Company completed the sale of the majority of these product lines for a cash purchase price, net of cash transferred and transaction costs, of $826 million and recognized a pretax gain on sale of $455 million ($305 million after tax). The divestiture of these product lines did not represent a strategic shift with a major effect on the Company’s operations and financial results and therefore is not reported as a discontinued operation.

X
- References No definition available. + Details
Name: | us-gaap_OtherIncomeAndExpensesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -URI http://asc.fasb.org/topic&trid=2122503 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 610 -URI http://asc.fasb.org/topic&trid=49130413 + Details
Name: | us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration